Announcements Trials
Browse Landscape

Status

Completed 7Withdrawn 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 40Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 1

Interventions

Surveys and Questionnaires 39Blood Specimen Collection 23Specimen Handling 14Radiotherapy 12Surgical Procedures, Operative 10Magnetic Resonance Spectroscopy 10Interviews as Topic 10Observation 9Drug Therapy 9Data Collection 8Immunotherapy 7Watchful Waiting 5Tomography, X-Ray Computed 5Radiosurgery 5Nivolumab 5Mental Status and Dementia Tests 5Mastectomy, Segmental 5Immune Checkpoint Inhibitors 5Biopsy 5ribociclib 4palbociclib 4lorlatinib 4Therapeutics 4Positron Emission Tomography Computed Tomography 4Magnetic Resonance Imaging 4Ipilimumab 4High-Throughput Nucleotide Sequencing 4Hepatectomy 4Echocardiography 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Observational × avelumab × Clear all
NCT06412848 2026-02-24

JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Active not recruiting
360 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡